Anti-inflammatory effects of infliximab and methotrexate on peripheral blood and synovial fluid mononuclear cells: ex vivo study
Authors' conclusion
Both IFX and MTX effectively inhibited PBMC proliferation and IFN-γ production, but only IFX reduced synovial monocytes and pro-inflammatory gene expression in SFMCs, suggesting a differential impact of IFX and MTX on critical inflammatory cell populations ex vivo.
Study context
- Population
- Peripheral blood mononuclear cells (PBMCs) of healthy donors and synovial fluid mononuclear cells (SFMCs) of psoriatic arthritis (PsA) and rheumatoid arthritis (RA) patients
- Comparison
- Infliximab (IFX) vs methotrexate (MTX) vs IFX + MTX on PBMCs and SFMCs ex vivo
- Outcome
- Inhibition of phytohaemagglutinin (PHA)-induced PBMC proliferation
Methodological detailsex vivo, flow cytometry, ELISA, quantitative PCR
- Ex vivo
- Flow cytometry
- ELISA
- Quantitative PCR
Main finding
As reported in the abstract
Further findings
| Outcome | IFX | MTX | IFX + MTX | Estimate | P value |
|---|---|---|---|---|---|
| Reduction of IFN-γ production in PHA-stimulated PBMCs | 68% | 90% | 85% | ||
| Reduction of CD14+CD16+ cells in SFMCs | reduction (PsA) 54% | P < 0.01 | |||
| Reduction of CD14+CD16+ cells in SFMCs | reduction (RA) 46% | P < 0.05 |
Reduction of CD14+CD16+ cells in SFMCs
- MTX had no effect on this population
- IFX + MTX: similar suppression as IFX alone
SFMC gene expression
- The drugs had different impacts on SFMC gene expression
Original publication
Anti-inflammatory effects of infliximab and methotrexate on peripheral blood and synovial fluid mononuclear cells: ex vivo study. Scand J Rheumatol. Published 26 January 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →